Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 3/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.32 |
| ▸ | MGLL | Q99685 | 2/20 | 0.32 |
| ▸ | RECQL | P46063 | 2/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | GUSB | P08236 | 2/20 | 0.30 |
| ▸ | EBP | Q15125 | 1/20 | 0.30 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4266267 | 0.91 | SMPD1 (0.34) | PTGS1PTGS2MGLLRECQLGLA | |
| SCHEMBL4023091 | 0.88 | SMPD1 (0.34) | RECQLGLAHPGDTSHRMAPK1 | |
| SCHEMBL15170123 | 0.88 | CA1 (0.33) | PTGS1PTGS2MGLLRECQLGLA | |
| SCHEMBL2295226 | 0.88 | CA1 (0.33) | PTGS1PTGS2MGLLRECQLGLA | |
| SCHEMBL13517070 | 0.88 | CA1 (0.33) | PTGS1PTGS2MGLLRECQLGLA | |
| SCHEMBL15170315 | 0.86 | CA1 (0.31) | — | |
| SCHEMBL514446 | 0.82 | EPHX1 (0.33) | — | |
| SCHEMBL1331130 | 0.82 | EPHX1 (0.33) | — | |
| SCHEMBL318567 | 0.82 | EPHX1 (0.33) | — | |
| SCHEMBL318176 | 0.82 | EPHX1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7999111-B2 | Reacting an onium halide or carboxylate with a symmetrically substituted dialkyl sulfite or with an asymmetrically substituted dialkyl sulfite; 1-hexyl-3-methylimidazolium chloride and dimethyl sulfite; 1-Hexyl-3-methylimidazolium methanesulfonate | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-08-16 | — | — | US | disclosed |
| US-20080221334-A1 | Process for the Preparation of Onium Alkylsulfonates | MERCK PATENT GESELLSCHAFT (DE) | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221334-A1 | Process for the Preparation of Onium Alkylsulfonates | STS, ARSA, AGPS | PTGS1 4282/4885PTGS2 3700/4885MGLL 276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.